UA96141C2 - Нейтрализующее антитело, которое имеет специфичность к человеческому il-6 - Google Patents

Нейтрализующее антитело, которое имеет специфичность к человеческому il-6

Info

Publication number
UA96141C2
UA96141C2 UAA200808897A UAA200808897A UA96141C2 UA 96141 C2 UA96141 C2 UA 96141C2 UA A200808897 A UAA200808897 A UA A200808897A UA A200808897 A UAA200808897 A UA A200808897A UA 96141 C2 UA96141 C2 UA 96141C2
Authority
UA
Ukraine
Prior art keywords
specificity
human
antibody
neutralising antibody
relates
Prior art date
Application number
UAA200808897A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ричард Эван Желинас
Митра Чудхури Сингхал
Йи Жанг
Эндрю Джордж Попплвэлл
Ральф Адамс
Original Assignee
Юсиби Фарма, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37714544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA96141(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Юсиби Фарма, С.А. filed Critical Юсиби Фарма, С.А.
Publication of UA96141C2 publication Critical patent/UA96141C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретение относится к гуманизированному нейтрализующему антителу, которое специфически связывается с человеческим IL-6, последовательности ДНК, которая его кодирует, вектору, клетке-хозяину, процессу изготовления антитела. Изобретение также относится к фармацевтической композиции, содержащей данное антитело, для применения в лечении или профилактике патологического расстройства, опосредованного IL-6 или связанного с ростом уровня IL-6.
UAA200808897A 2005-12-09 2006-12-04 Нейтрализующее антитело, которое имеет специфичность к человеческому il-6 UA96141C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74892605P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
UA96141C2 true UA96141C2 (ru) 2011-10-10

Family

ID=37714544

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200808897A UA96141C2 (ru) 2005-12-09 2006-12-04 Нейтрализующее антитело, которое имеет специфичность к человеческому il-6

Country Status (27)

Country Link
US (5) US8075889B2 (ru)
EP (3) EP2336181A1 (ru)
JP (1) JP5183484B2 (ru)
KR (2) KR101413451B1 (ru)
CN (1) CN101356194B (ru)
AR (1) AR057224A1 (ru)
AU (1) AU2006323490B2 (ru)
BR (1) BRPI0619595B8 (ru)
CA (1) CA2632628C (ru)
DK (1) DK1960430T3 (ru)
EA (1) EA018044B1 (ru)
EC (1) ECSP088613A (ru)
ES (1) ES2525325T3 (ru)
HR (1) HRP20141214T1 (ru)
IL (2) IL191600A (ru)
MY (1) MY147217A (ru)
NO (1) NO344847B1 (ru)
NZ (1) NZ569234A (ru)
PE (1) PE20070998A1 (ru)
PL (1) PL1960430T3 (ru)
PT (1) PT1960430E (ru)
RS (1) RS53708B1 (ru)
SI (1) SI1960430T1 (ru)
TW (1) TWI390035B (ru)
UA (1) UA96141C2 (ru)
WO (1) WO2007066082A1 (ru)
ZA (1) ZA200804594B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
EP2336181A1 (en) * 2005-12-09 2011-06-22 UCB Pharma, S.A. Antibody molecules having specificity for human IL-6
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
CA2693310C (en) * 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
WO2009140348A2 (en) 2008-05-13 2009-11-19 Novimmune Sa Anti-il-6/il-6r antibodies and methods of use thereof
CA2742786A1 (en) * 2008-11-13 2010-05-20 Femta Pharmaceuticals, Inc. Humanized anti-il-6 antibodies
CA2744400C (en) 2008-11-25 2019-01-15 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
AU2010283997B2 (en) * 2009-08-21 2015-04-09 Gilead Biologics, Inc. Methods and compositions for treatment of pulmonary fibrotic disorders
EP2467396A4 (en) * 2009-08-21 2012-12-26 Gilead Biologics Inc CATALYTIC DOMAINS FROM LYSYL OXIDASE AND LOXL2
US8680246B2 (en) * 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
US9304134B2 (en) 2010-11-23 2016-04-05 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of anemia
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
US9289467B2 (en) * 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
WO2013086419A1 (en) * 2011-12-09 2013-06-13 California Institute Of Technology Polymer scaffolds and their use in the treatment of vision loss
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
KR102321372B1 (ko) * 2012-10-22 2021-11-11 원니스 바이오테크 컴퍼니 리미티드 인터류킨-6에 대한 항체 및 그의 용도
US20150239970A1 (en) * 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
KR20190031439A (ko) * 2016-05-05 2019-03-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Il-6 및 cd126을 표적으로 하는 dna 단클론성 항체
US20200306283A1 (en) 2016-06-22 2020-10-01 William Warren HARLESS Cancer treatment and metastasis inhibition using an anti-cancer stem cell agent in combination with a neu1 sialidase inhibitor or a cytokine inhibitor after primary cancer treatment
CN106413047A (zh) * 2016-10-31 2017-02-15 北京小米移动软件有限公司 智能设备接入无线网络的方法和装置
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
KR20200012823A (ko) 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료
JP6950242B2 (ja) * 2017-03-31 2021-10-13 ブラザー工業株式会社 通信装置
CA3087699A1 (en) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression
CN112512572B (zh) 2018-04-20 2024-12-10 礼进生物医药科技（上海）有限公司 抗cd40抗体及其用途
CN112996818B (zh) 2018-09-28 2022-06-21 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
KR20220103957A (ko) * 2019-10-23 2022-07-25 리브젠 바이오파마 홀딩스 리미티드 항-cd40 결합 분자 및 이를 포함하는 이중-특이적 항체
IL307544A (en) * 2021-04-08 2023-12-01 Sana Biotechnology Inc Cd8-specific antibody constructs and compositions thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
CA1341588C (en) * 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
IL88375A (en) * 1988-11-14 1995-07-31 Yeda Res & Dev Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5856135A (en) * 1993-05-31 1999-01-05 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6
JP3614183B2 (ja) * 1993-05-31 2005-01-26 中外製薬株式会社 ヒトインターロイキン−６に対する再構成ヒト抗体
FR2707882B1 (fr) * 1993-07-23 1997-08-01 Immunotech Sa Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant.
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
AU736282B2 (en) * 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
BRPI0214168B8 (pt) * 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
JP4463104B2 (ja) * 2002-08-30 2010-05-12 財団法人化学及血清療法研究所 ヒト抗ヒトインターロイキン−６抗体及び該抗体フラグメント
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
EP2336181A1 (en) 2005-12-09 2011-06-22 UCB Pharma, S.A. Antibody molecules having specificity for human IL-6

Also Published As

Publication number Publication date
CN101356194B (zh) 2013-06-12
ZA200804594B (en) 2010-08-25
RS53708B1 (sr) 2015-04-30
US9096668B2 (en) 2015-08-04
CA2632628C (en) 2016-01-19
IL191600A0 (en) 2008-12-29
EP1960430B1 (en) 2014-09-24
WO2007066082A1 (en) 2007-06-14
BRPI0619595B1 (pt) 2020-09-15
KR101413451B1 (ko) 2014-07-10
BRPI0619595A2 (pt) 2011-10-04
KR20130100386A (ko) 2013-09-10
PE20070998A1 (es) 2007-10-09
ECSP088613A (es) 2008-08-29
AU2006323490A1 (en) 2007-06-14
HK1125113A1 (en) 2009-07-31
ES2525325T3 (es) 2014-12-22
US20120183996A1 (en) 2012-07-19
NZ569234A (en) 2011-07-29
AR057224A1 (es) 2007-11-21
PT1960430E (pt) 2015-01-05
AU2006323490B2 (en) 2012-05-24
CA2632628A1 (en) 2007-06-14
US8075889B2 (en) 2011-12-13
JP2009518023A (ja) 2009-05-07
EP2314626A1 (en) 2011-04-27
EA200801427A1 (ru) 2008-12-30
US20070154481A1 (en) 2007-07-05
CN101356194A (zh) 2009-01-28
EA018044B1 (ru) 2013-05-30
JP5183484B2 (ja) 2013-04-17
IL191600A (en) 2015-11-30
BRPI0619595B8 (pt) 2022-12-13
KR20080077271A (ko) 2008-08-21
NO344847B1 (no) 2020-05-25
US8486662B2 (en) 2013-07-16
NO20083066L (no) 2008-09-08
EP1960430A1 (en) 2008-08-27
US20170182159A1 (en) 2017-06-29
US20160039929A1 (en) 2016-02-11
TWI390035B (zh) 2013-03-21
BRPI0619595A8 (pt) 2019-01-15
PL1960430T3 (pl) 2015-03-31
KR101422523B1 (ko) 2014-07-24
IL242434B (en) 2018-04-30
SI1960430T1 (sl) 2015-01-30
DK1960430T3 (da) 2015-01-05
US9631015B2 (en) 2017-04-25
EP2336181A1 (en) 2011-06-22
HRP20141214T1 (hr) 2015-02-13
TW200728466A (en) 2007-08-01
MY147217A (en) 2012-11-14
US20140024077A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
UA96141C2 (ru) Нейтрализующее антитело, которое имеет специфичность к человеческому il-6
MX349095B (es) Moleculas biespecificas de union a antigeno.
EP4487869A3 (en) Rna encoding a tumor antigen
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
PH12013500356A1 (en) Engineered anti-tslp antibody
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
MX2009003973A (es) Moleculas de anticuerpo que unen il-17 e il-17f.
EA201492149A8 (ru) St2-антигенсвязывающие белки
PH12013502205A1 (en) Antibodies to il-6 and their uses
TW200745162A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
WO2007042309A3 (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
MX2014006158A (es) Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa.
EA200970874A1 (ru) Антитела против склеростина
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
MY157173A (en) Modified humanised anti-interleukin-18
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
JO3097B1 (ar) الأجسام المضادة c-Met
MX361929B (es) Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
MX2010010387A (es) Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
MX2009013410A (es) Biomarcadores para predecir capacidad de respuesta anti-tnf o sin capacidad de respuesta.
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
UA105384C2 (ru) Лечение нарушений, связанных с инсулинорезистентностью
MX354743B (es) Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi).